The Strategic Asymmetry

Why Some Investments Create More Options Than Others

Not every investment creates the same amount of future value.

Two investments can require the same AED 5 million.

One may produce a predictable return for several years.

The other may produce a smaller immediate return—but open a new market, create proprietary data, establish a strategic partnership, build a new organizational capability or create several opportunities that did not previously exist.

Financially, the first investment may look better.

Strategically, the second may be far more valuable.

This is Strategic Asymmetry™.

The principle is simple:

Some investments create returns. Others create returns while increasing the number of valuable choices available to the organization.

The difference can become enormous over time.

Not All Capital Creates the Same Future

Healthcare leaders understandably evaluate investments through familiar measures:

ROI.

EBITDA impact.

Payback period.

Revenue growth.

Cost reduction.

These measures matter.

But they can miss an important strategic dimension:

What does this investment make possible next?

Consider an investment in a new specialty service.

Its immediate value may be the revenue generated by that service.

Its strategic value could be much larger if it also creates:

• access to a new patient population;

• relationships with new referral sources;

• new clinical capabilities;

• additional data;

• payer relationships;

• opportunities for adjacent services;

• geographic expansion possibilities.

The investment has created more than one outcome.

It has increased the organization's strategic surface area.

That is where asymmetry begins.

The Second-Order Return

The most sophisticated investors do not look only at the first return.

They consider the second-order effects.

An investment in a digital platform might initially appear to be a technology expense.

But if it creates proprietary patient data, improves consumer engagement, enables new care models and provides the infrastructure for AI-enabled services, its strategic value may extend far beyond the original business case.

A partnership may initially generate modest revenue.

But if it provides access to a new geography, specialized expertise or a new patient segment, it may create options that would have been expensive or impossible to build independently.

McKinsey's research on healthcare diversification has similarly highlighted how partnerships and investments can provide access to differentiated talent, technology, market insights and capabilities—not simply financial returns.

The question therefore becomes:

What is the investment worth because of what it enables—not just because of what it produces?

The Most Valuable Asset May Be a New Capability

Healthcare organizations often invest in assets.

The more strategically sophisticated question is whether they are investing in capabilities.

A new facility is an asset.

The ability to launch new services repeatedly is a capability.

A new technology platform is an asset.

The ability to continuously translate data into better decisions is a capability.

A partnership is an arrangement.

The ability to build and manage high-value partnerships may become a capability.

Capabilities compound because they can be used repeatedly.

That means one investment can become the foundation for multiple future investments.

McKinsey's recent analysis of healthcare dealmaking found that healthcare organizations are increasingly using M&A and other investments to obtain new capabilities and enhance existing assets—not simply to expand into new markets.

That is a significant shift in how strategic capital should be evaluated.

Strategic Freedom Has Value

Imagine two healthcare organizations facing the same market disruption.

Organization A has optimized its existing business for maximum near-term efficiency.

Organization B has deliberately invested in data, partnerships, technology, leadership capabilities and adjacent service models.

Both may have similar current profitability.

But Organization B has more ways to respond.

It can enter a new market.

Partner with a new player.

Launch a new service.

Redeploy its capabilities.

Use its data differently.

Expand geographically.

The second organization possesses something that does not appear neatly on a balance sheet:

Strategic freedom.

Rita McGrath's work on competitive advantage and real options has emphasized the strategic value of investments that create the right—but not the obligation—to make larger commitments when uncertainty becomes clearer.

This is particularly relevant in healthcare, where regulation, technology, consumer behavior, reimbursement and care models continue to evolve.

The Danger of Optimizing Only for Today

Short-term financial discipline is essential.

But an organization can become so focused on optimizing today's economics that it underinvests in tomorrow's possibilities.

The danger is subtle.

Every investment decision looks rational.

Every project has a hurdle rate.

Every budget protects current performance.

Yet the organization gradually becomes less capable of entering new markets, responding to disruption or pursuing opportunities.

It becomes efficient—but strategically constrained.

This is why McKinsey has emphasized active capital reallocation in healthcare and the importance of directing resources toward future growth opportunities rather than allowing capital to remain anchored to historical allocations.

The strategic question is not simply:

“Will this investment pay back?”

It is:

“What choices will we have because we made it?”

Measure the Option Value

Phoenix MedStrategy's Strategic Asymmetry™ asks leaders to evaluate investments across two dimensions:

Immediate Return

What does this investment produce today?

Future Optionality

What does this investment make possible tomorrow?

An investment becomes particularly powerful when it performs reasonably well on both.

It generates economic value and expands the organization's strategic choices.

That might mean:

New market access.

New data.

New capabilities.

New partnerships.

New service opportunities.

New geographic options.

The goal is not to pursue every possible option.

That would create its own form of strategic complexity.

The goal is to deliberately invest in high-value choices.

The Capital Allocation Test

Before approving the next major investment, healthcare leaders should ask:

What immediate return will this produce?

What capability will it create?

What new market could it unlock?

What data or intelligence could it generate?

Which partnerships could become possible?

What future investment would become easier because of this one?

And perhaps the most important question:

Are you allocating capital for today's return—or deliberately increasing the number of valuable choices available to you tomorrow?

That is the difference between capital allocation and strategic capital allocation.

The strongest organizations do not simply spend capital to become bigger.

They use capital to become more capable, more adaptable and harder to constrain.

Because the best investment may not be the one with the highest immediate return.

It may be the one that gives you more attractive places to go next.

At Phoenix MedStrategy, we help healthcare leaders evaluate growth and investment decisions not only by their immediate economics, but by the capabilities, relationships and strategic options they create for the future.

Today's investment should not close tomorrow's choices.

It should create better ones.

Sources

• McGrath, Rita Gunther. “A New Approach to Innovation Investment.” Harvard Business Review, 2008.

• McGrath, Rita Gunther. The End of Competitive Advantage: How to Keep Your Strategy Moving as Fast as Your Business. Harvard Business Review Press, 2013.

• McGrath, Rita Gunther. “The Power of Strategic Centering.” Harvard Business Review, July–August 2026.

• McKinsey & Company. “US health systems diversify for growth.”

• McKinsey & Company. “Healthcare transformation: The value of partnerships.”

• McKinsey & Company. “US healthcare: Companies continue to create value through diversification,” 2026.

• McKinsey & Company. “An opportunity to reorder the healthcare industry.”